Close
Close
GLOW Blend: GHK-Cu / BPC-157 / TB-4

GLOW Blend: GHK-Cu / BPC-157 / TB-4 3-Month Membership Program

$1,550.00

4.9 Avg. Rating

1000+ Reviews

  • Follow-up Exam
  • Lab Review
  • Dose Adjustments
  • Certificate of Authenticity
  • 503A Pharmacies
  • 99% Pure
  • US-based Peptides
The GLOW Blend is a name used for a combination of three peptides, GHK-Cu, BPC-157, and Thymosin Beta-4 (often referred to as TB-4 or TB-500), that patients sometimes ask about when they’re interested in both skin health and broader tissue recovery. The name reflects the goal behind combining them, supporting a healthy, resilient appearance alongside general tissue repair, but it’s important to understand this is a descriptive nickname rather than a scientifically established outcome.
Each peptide in this blend has its own distinct research background. GHK-Cu is a naturally occurring copper-binding peptide studied for its role in collagen production and skin health, with a relatively well-established human research base for topical use. BPC-157 is a synthetic peptide based on a fragment of a protective stomach protein, studied primarily in animal research for tissue and gut healing. Thymosin Beta-4 is a naturally occurring protein studied for its role in cell movement and structural organization within cells, which is relevant to how tissues repair themselves.
Patients commonly ask about this combination because they’re hoping to address both visible skin health and broader tissue recovery within one plan. It’s important to understand upfront that this specific three-peptide combination has not been directly studied together in dedicated human research, and two of the three components, BPC-157 and Thymosin Beta-4, still have a more limited human evidence base and an evolving regulatory status.
This page provides an honest look at what’s known about each individual component, so you and your provider can have a realistic, informed conversation about this blend.
To understand the GLOW Blend, it helps to think of it as addressing three different aspects of tissue health. GHK-Cu is studied for its role in stimulating collagen production and helping deliver copper, an important mineral for connective tissue, to areas of the skin that need support, like reinforcing the structural frame beneath the skin’s surface. BPC-157 is studied for its potential role in supporting new blood vessel growth to injured tissue, helping deliver oxygen and nutrients where they’re needed for repair. Thymosin Beta-4 works through yet another pathway, interacting with a structural protein inside cells called actin, which influences how cells move and organize themselves, a process relevant to cells traveling to an area of stress or injury to begin repair. Because these three peptides are studied through different, complementary mechanisms, some providers have proposed combining them to address skin health and tissue repair from multiple angles at once. It’s important to understand that this rationale is built by combining what’s known about each peptide separately rather than from direct research on this specific three-peptide combination.
  • Has shown promise in research, when considering GHK-Cu individually, for supporting collagen production, skin firmness, and wound healing
  • Is currently being studied, when considering BPC-157 individually, for its potential role in supporting tissue repair, largely based on animal research
  • May be of interest, when considering Thymosin Beta-4 individually, for its studied role in cellular movement relevant to tissue healing
  • Is being explored by some providers as a combined approach to address both skin health and broader tissue recovery within one plan
Because this specific three-peptide combination has not been studied together in human clinical trials, these potential benefits should be understood as a reasonable but still theoretical extension of each peptide’s individual research, not a proven combined effect.
Patients who commonly ask about the GLOW Blend include those interested in:
  • Skin health and healthy aging, particularly patients interested in GHK-Cu’s more established research on collagen and skin firmness
  • Athletic recovery, for patients also interested in broader tissue support through BPC-157 and Thymosin Beta-4
  • Wellness optimization, for patients working with a provider on a broader skin and recovery plan
This combination is not appropriate for everyone, and given the limited human research on two of its three components, and the lack of direct research on the combination itself, it requires a particularly thorough and honest conversation with a licensed provider before starting.
Each component of this blend has its own research base, described in more detail on their dedicated pages. GHK-Cu has a relatively well-established human research history, particularly for topical use, with generally positive findings related to skin collagen, firmness, and some wound-healing measures, though results have been more mixed for certain types of chronic wounds. BPC-157 has an extensive animal and laboratory research history but a much more limited human clinical trial base, and its regulatory status for pharmacy compounding has changed over time. Thymosin Beta-4 has also been studied primarily in laboratory and animal research related to cell migration and tissue regeneration, and it’s worth noting that Thymosin Beta-4 and its derivatives are classified as prohibited substances by sports anti-doping authorities, which is relevant for competitive athletes. It’s important to be transparent that no dedicated human clinical trials have examined this specific three-peptide combination together. The rationale for combining them comes from extrapolating each peptide’s individual research rather than from direct evidence of a combined effect in humans. Because two of the three components have more limited human data and an evolving regulatory landscape, this combination should be approached as a developing area of interest rather than an established, well-studied therapy.
Available research on GHK-Cu generally has not identified serious safety concerns, particularly for topical use. BPC-157 and Thymosin Beta-4 have also generally shown mild side effect profiles in the more limited research available, most commonly injection site reactions, though comprehensive long-term human safety data for these two components remains limited. Because no dedicated human research exists on the combination of all three peptides together, safety information for this specific blend should be considered incomplete rather than fully established. This combination requires an especially thorough conversation with your provider, including a full review of your medical history, and consideration of any relevant factors such as competitive athletic status, given the anti-doping classification of Thymosin Beta-4. Patients with certain active health conditions, or known copper sensitivities relevant to the GHK-Cu component, may not be appropriate candidates. This is not a complete list of contraindications, and only a licensed provider can help you understand whether this combination is a reasonable option to explore. Ongoing medical supervision is especially important given the varying levels of evidence and the evolving regulatory picture for the different components of this blend.

What does the GLOW Blend do?

It combines GHK-Cu, BPC-157, and Thymosin Beta-4, three peptides studied individually for their potential roles in skin health, tissue repair, and cellular movement.

Is the GLOW Blend FDA-approved?

No. None of the three components has FDA approval as a prescription drug, and BPC-157 and Thymosin Beta-4 in particular have an evolving regulatory status for pharmacy compounding.

How long before I may notice changes?

Responses vary considerably, and because dedicated human research on this combination doesn’t exist, there is no well-established timeline for expected results.

Is it an injection?

The components can be used topically (particularly GHK-Cu) or by injection, and your provider will discuss the appropriate approach for your specific goals.

Can it be combined with other peptides?

This should always be discussed with your provider, who can evaluate your full treatment plan and goals.

Can it be combined with GLP-1 medications?

This should be discussed individually with your provider as part of your overall treatment plan.

Will I need lab work?

Your provider may recommend baseline evaluation as part of a thorough, individualized approach to this combination therapy.

Who should avoid this peptide combination?

Patients with certain active health conditions, known copper sensitivities, or competitive athletes subject to anti-doping testing should have a particularly careful conversation with their provider.

How long do patients typically remain on therapy?

Treatment length varies by individual goals, and given the evolving evidence base for some components, your provider will help determine a reasonable, individualized plan.

Is a consultation required?

Yes. A telehealth consultation with a licensed medical provider is required before starting the GLOW Blend or any peptide therapy at SevenHealth.
Every peptide treatment program at SevenHealth is built around comprehensive, individualized medical care. When you begin therapy, your program includes:
  • An initial telehealth medical history and comprehensive evaluation with a licensed medical provider
  • Review of previous laboratory results when available, or recommendations for laboratory testing when medically appropriate
  • Personalized treatment recommendations based on your medical history and goals
  • Three months of prescribed peptide therapy when medically appropriate
  • A customized dosing and titration schedule specific to your prescribed peptides
  • A comprehensive follow-up appointment approximately three months after starting treatment
  • Review of progress, discussion of results, treatment adjustments if medically appropriate, and continued provider guidance
  • Ongoing provider oversight throughout your treatment program
  • No additional fees for appointments included within the treatment program
  • No additional fees for laboratory review as part of your treatment
Our goal is to make your experience with peptide therapy simple, transparent, and medically supervised from your very first consultation through every follow-up appointment. Given the varying levels of evidence and the evolving regulatory picture surrounding some components of this blend, your provider will keep you informed of current availability and realistic expectations throughout your care.
Patients choose SevenHealth because we focus on individualized, medically supervised care rather than one-size-fits-all protocols. Every treatment plan is built around your specific health history and goals, and every prescription is overseen by a licensed medical provider from start to finish. We work with FDA-registered 503A U.S. compounding pharmacies that follow applicable quality standards, so you can feel confident in the source and handling of your prescribed peptide therapy, to the extent current regulations allow. Dosing is guided by your provider, not guesswork, and every program includes a three-month follow-up to review your progress and make adjustments if needed. We also believe in transparent pricing and honest education. There are no surprise appointment fees or lab review fees hidden within your treatment program, and we believe in giving patients a clear, accurate picture of where the science and regulatory landscape currently stand for each component of a combination like this one.
  • The GLOW Blend combines GHK-Cu, BPC-157, and Thymosin Beta-4, three peptides studied individually for skin, tissue, and cellular repair support.
  • GHK-Cu has a relatively well-established human research base, particularly for topical use; BPC-157 and Thymosin Beta-4 have more limited human data.
  • No dedicated human research exists on this specific three-peptide combination used together.
  • Thymosin Beta-4 is classified as a prohibited substance in many competitive sports contexts.
  • BPC-157 and Thymosin Beta-4’s regulatory status for pharmacy compounding has changed over time and continues to be reviewed.
  • Available safety data for each individual component generally suggests mild side effects, but comprehensive data on the combination is not available.
  • This combination requires an especially thorough, honest conversation with your provider.
  • SevenHealth includes an initial evaluation, personalized dosing, lab review, and a three-month follow-up in every treatment program.

Educational Disclaimer

This information is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapy should only be used under the supervision of a licensed healthcare provider after an appropriate medical evaluation. Individual results may vary.

$100 OFF GLP-1 Injectable Plans for New Members ! CODE: